Sign up
Log in
George
China-Coronavirus/Vaccine Trial
Beijing, China - May 23, 2020 (CCTV - No access Chinese mainland)
1. Screenshots of article about China's COVID-19 vaccine trial
2. Screenshot of twitter post by The Lancet editor-in-chief Richard Horton
Beijing, China - Recent (CCTV - No access Chinese mainland)
3. Various of researchers working
4. Picture of COVID-19 vaccine for clinical trials
5. Sign reading "Inactivated COVID-19 Vaccine Manufacturing Campus"
FILE: Beijing, China - April 14, 2020 (CGTN - No access Chinese mainland)
6. Various of researchers working, test tubes
7. Various of inactivated vaccines for COVID-19
FILE: Wuhan City, Hubei Province, central China - April 12, 2020 (CCTV - No access Chinese mainland)
8. Various of volunteers, medics in hospital, poster reading "Recombinant COVID-19 Vaccine Phase Two Clinical Study"
China's COVID-19 vaccine trial, the first such vaccine to reach phase one clinical trial, has been found to be safe, well-tolerated, and able to generate an immune response against SARS-CoV-2 in humans, according to a study published online Friday by the medical journal The Lancet.
The open-label trial in 108 healthy adults demonstrates promising results after 28 days and the final results will be evaluated in six months, The Lancet said in a press statement.
Further trials are needed to tell whether the immune response it elicits can effectively protect against SARS-CoV-2 infection, said the medical journal.
The trial demonstrates that a single dose of the new adenovirus type 5 vectored COVID-19 (Ad5-nCoV) vaccine produces virus-specific antibodies and T cells in 14 days, making it a potential candidate for further investigation.
A randomized, double-blinded, placebo-controlled phase two trial of the Ad5-nCoV vaccine has been initiated in the central Chinese city of Wuhan to determine whether the results can be replicated. And if there are any adverse events up to six months after vaccination in 500 healthy adults: 250 volunteers given a middle dose, 125 given a low dose, and 125 given a placebo as a control, according to The Lancet.
Richard Horton, editor-in-chief of The Lancet, shared the result on Twitter, saying "These results represent an important milestone".
China-Coronavirus/Vaccine Trial
Dateline : May 22, 2020/Recent/File
Location : China
Duration : 1'04
Beijing, China - May 23, 2020 (CCTV - No access Chinese mainland)
1. Screenshots of article about China's COVID-19 vaccine trial
2. Screenshot of twitter post by The Lancet editor-in-chief Richard Horton
Beijing, China - Recent (CCTV - No access Chinese mainland)
3. Various of researchers working
4. Picture of COVID-19 vaccine for clinical trials
5. Sign reading "Inactivated COVID-19 Vaccine Manufacturing Campus"
FILE: Beijing, China - April 14, 2020 (CGTN - No access Chinese mainland)
6. Various of researchers working, test tubes
7. Various of inactivated vaccines for COVID-19
FILE: Wuhan City, Hubei Province, central China - April 12, 2020 (CCTV - No access Chinese mainland)
8. Various of volunteers, medics in hospital, poster reading "Recombinant COVID-19 Vaccine Phase Two Clinical Study"
China's COVID-19 vaccine trial, the first such vaccine to reach phase one clinical trial, has been found to be safe, well-tolerated, and able to generate an immune response against SARS-CoV-2 in humans, according to a study published online Friday by the medical journal The Lancet.
The open-label trial in 108 healthy adults demonstrates promising results after 28 days and the final results will be evaluated in six months, The Lancet said in a press statement.
Further trials are needed to tell whether the immune response it elicits can effectively protect against SARS-CoV-2 infection, said the medical journal.
The trial demonstrates that a single dose of the new adenovirus type 5 vectored COVID-19 (Ad5-nCoV) vaccine produces virus-specific antibodies and T cells in 14 days, making it a potential candidate for further investigation.
A randomized, double-blinded, placebo-controlled phase two trial of the Ad5-nCoV vaccine has been initiated in the central Chinese city of Wuhan to determine whether the results can be replicated. And if there are any adverse events up to six months after vaccination in 500 healthy adults: 250 volunteers given a middle dose, 125 given a low dose, and 125 given a placebo as a control, according to The Lancet.
Richard Horton, editor-in-chief of The Lancet, shared the result on Twitter, saying "These results represent an important milestone".
ID : 8144014
Published : 2020-05-23 11:35
Last Modified : 2020-05-23 19:30:00
Source : China Central Television (CCTV)
Restrictions : No access Chinese mainland
More
